Medicenna Therapeutics (TSE:MDNA) Shares Down 18.2% – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price was down 18.2% during mid-day trading on Thursday . The stock traded as low as C$0.51 and last traded at C$0.54. Approximately 193,189 shares traded hands during mid-day trading, an increase of 80% from the average daily volume of 107,333 shares. The stock had previously closed at C$0.66.

Medicenna Therapeutics Trading Down 13.6%

The stock has a 50 day moving average of C$0.67 and a 200 day moving average of C$0.97. The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65. The firm has a market cap of C$47.55 million, a P/E ratio of -3.80 and a beta of 2.90.

Medicenna Therapeutics (TSE:MDNA) last posted its quarterly earnings data on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. As a group, equities research analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.